Reata Pharmaceuticals: Q2 Earnings Insights

Shares of Reata Pharmaceuticals RETA decreased in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 7.32% over the past year to ($1.32), which beat the estimate of ($2.08).

Revenue of $2,221,000 decreased by 27.73% from the same period last year, which beat the estimate of $1,250,000.

Guidance

Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 09, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=3196578&sessionid=1&key=57A5A4A99C3D3BA0F2D6A7D9D86B06B7&regTag=&V2=false&sourcepage=register

Price Action

Company's 52-week high was at $186.82

52-week low: $76.34

Price action over last quarter: Up 14.04%

Company Description

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!